Kilatim

Timolol maleate and Latanoprost, the active ingredients in Kilatim, are a beta‑blocker and a prostaglandin analog presented as an ophthalmic solution for ocular use. They treat primary open‑angle glaucoma and ocular hypertension in adults. GNH USA supplies Kilatim as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kilatim, a combination beta‑blocker and prostaglandin analog, is used to manage intra‑ocular pressure in glaucoma and ocular hypertension. Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers eye pressure to prevent conversion to glaucoma. Normal‑tension glaucoma: helps control pressure when optic nerve damage is present despite normal pressure readings.

Common Side Effects: - Eye irritation or burning sensation. - Blurred vision shortly after instillation. - Redness of the conjunctiva. - Dry eye or foreign‑body feeling. Serious or Rare Side Effects: - Severe allergic reaction with swelling of the eyelid. - Ocular inflammation or uveitis. - Sudden loss of vision. - Systemic bradycardia or bronchospasm, especially in susceptible patients.

Before using Kilatim, consider the following precautions: - Assess cardiovascular status: avoid in patients with severe bradycardia or heart block. - Monitor respiratory condition: use with caution in asthma or COPD. - Check for sulfonamide allergy: latanoprost may trigger hypersensitivity. - Avoid concurrent ocular beta‑blockers: risk of additive hypotensive effect. - Store at room temperature: keep in the original container, protect from light and moisture.

Kilatim may interact with other medicines as follows: Major Interactions (Avoid): - Systemic non‑selective beta‑blockers: additive bradycardia. - Beta‑agonist inhalers (e.g., albuterol): reduced timolol efficacy. - Other prostaglandin analog eye drops: increased ocular inflammation. - MAO inhibitors: potential systemic interaction with timolol. Moderate Interactions (Monitor Closely): - Systemic carbonic anhydrase inhibitors: may affect intra‑ocular pressure control. - Topical corticosteroids: may diminish latanoprost effect.